Stockscreener 앱 받기
1.0068
2.98%
-0.0332
전일 마감가:
$1.04
열려 있는:
$1.03
하루 거래량:
2.74M
Relative Volume:
0.50
시가총액:
$292.03M
수익:
-
순이익/손실:
$-63.08M
주가수익비율:
-3.7289
EPS:
-0.27
순현금흐름:
$-72.53M
1주 성능:
-12.26%
1개월 성능:
-7.43%
6개월 성능:
+42.11%
1년 성능:
-44.86%
1일 변동 폭
$0.9923
$1.06
1주일 범위
$0.9923
$1.19
52주 변동 폭
$0.515
$1.80
오큐젠 Stock (OCGN) Company Profile
명칭
Ocugen Inc
전화
484-328-4701
주소
11 GREAT VALLEY PARKWAY, MALVERN, PA
OCGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
1.00 | 330.00M | 0 | -63.08M | -72.53M | -0.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
466.39 | 123.00B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.10 | 59.66B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.33 | 41.84B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
570.62 | 33.98B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
288.55 | 27.67B | 3.81B | -644.79M | -669.77M | -6.24 |
오큐젠 Stock (OCGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-15 | 개시 | Maxim Group | Buy |
| 2023-03-01 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2022-08-23 | 개시 | Mizuho | Buy |
| 2022-06-15 | 재개 | ROTH Capital | Buy |
| 2022-06-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-07-26 | 개시 | Noble Capital Markets | Outperform |
| 2021-06-11 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2021-05-07 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-09 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2021-02-04 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
모두보기
오큐젠 주식(OCGN)의 최신 뉴스
Ocugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results - Ocugen
Ocugen to Host Conference Call on Friday, August 1 at 8:30 - GlobeNewswire
Ocugen Earnings: Gene Therapy Pioneer to Report Q2 2025 Results August 1 - Stock Titan
Stargardt Disease Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Nanoscope Therapeutics, Belite Bio, Biophytis, reVision Therapeutics, Inc - The Globe and Mail
Ouster Announces Date for Second Quarter 2025 Earnings Call - The Globe and Mail
Building Biotech Champions: Cultivating Breakthroughs In A Dynamic Field - Life Science Leader
OCGN ALERT– Nationally Ranked Shareholder Rights Firm Labaton Sucharow is Investigating Ocugen, Inc. (NASDAQ: OCGN) For Potential Securities Violations and Breach of Fiduciary Duty - ACCESS Newswire
Ocugen receives additional 180-day extension from Nasdaq to meet $1 minimum bid - Investing.com
How did OCGN's Q4 earnings surprise impact its annual performance? - AInvest
After laying off most of its staff, struggling Carisma Therapeutics finds a merger partner - The Business Journals
Ocugen stock steady as H.C. Wainwright reiterates buy rating By Investing.com - Investing.com South Africa
Major Biotech Merger: Carisma and OrthoCellix Unite to Advance Revolutionary Knee Cartilage Treatment - Stock Titan
Ocugen Receives FDA Clearance for Phase 2/3 Trial of Genetic Therapy for Stargardt Disease - MSN
Ocugen: Three Potential Gene-Therapy Filings By 2028 (NASDAQ:OCGN) - Seeking Alpha
FDA clears Ocugen’s IND amendment for trial of Stargardt disease treatment - Yahoo Finance
Ocugen to Release New Investor Presentation - TipRanks
Ocugen gets FDA clearance to begin mid-stage study of OCU410ST - MSN
OCGN Gains as FDA Approves Trial for Stargardt Disease Therapy - GuruFocus
Ocugen (OCGN) Stock Soars On FDA Clearance For Pivotal Stargardt Disease Trial - Benzinga
Ocugen gets FDA nod to begin mid-stage study of OCU410ST (OCGN) - Seeking Alpha
Ocugen’s IND amendment to begin phase 2/3 confirmatory trial of OCU410ST cleared by FDA - Ophthalmology Times
Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease - Ocugen
Ocugen Gets FDA Clearance to Start Phase 2/3 Stargardt Disease Trial - MarketScreener
Ocugen (OCGN) Receives FDA Clearance for Key Gene Therapy Trial - GuruFocus
Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New - GuruFocus
FDA clears Ocugen’s phase 2/3 trial for Stargardt disease therapy - Investing.com
Ocugen to Showcase Gene Therapy Advancements at 2025 BIO International Convention - MSN
Ocugen To Present at BIO International Convention 2025 | OCGN St - GuruFocus
Ocugen To Present at BIO International Convention 2025 - Ocugen
Ocugen To Present at BIO International Convention 2025 | OCGN Stock News - GuruFocus
Ocugen, Inc. to Present at 2025 BIO International Convention, Showcasing Gene Therapy Advancements for Blindness Diseases - Nasdaq
Ocugen Showcases Breakthrough Blindness Gene Therapy Platform at BIO 2025 After Korean Partnership Deal - Stock Titan
Ocugen Reports Progress in Q1 2025 with Advancements in Gene Therapy - MSN
Ocugen Secures Licensing Agreement for OCU400 in Korea - MSN
Ocugen signs term sheet for Korean licensing of OCU400 gene therapy - Modern Retina
Ocugen signs license deal with Korean company for gene therapy - MSN
Ocugen, Inc. (NASDAQ:OCGN) Position Boosted by Wellington Management Group LLP - Defense World
Ameriprise Financial Inc. Invests $30,000 in Ocugen, Inc. (NASDAQ:OCGN) - Defense World
Ocugen Signs License Agreement for OCU400 in Korea - TipRanks
Ocugen signs term sheet for korean licensing of OCU400 gene therapy - Ophthalmology Times
Ocugen stock rises on Korean licensing deal for gene therapy By Investing.com - Investing.com Nigeria
Ocugen stock rises on Korean licensing deal for gene therapy - Investing.com Australia
Ocugen (OCGN) Secures Licensing Deal for Gene Therapy in Korea - GuruFocus
Ocugen stock gains on licensing deal (OCGN:NASDAQ) - Seeking Alpha
BNP Paribas Financial Markets Acquires Shares of 36,859 Ocugen, Inc. (NASDAQ:OCGN) - Defense World
Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of Ocu400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea - MarketScreener
Ocugen inks $11 million gene therapy deal for Korean market - Investing.com Australia
Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea - Ocugen
Ocugen Signs Deal for Korean Rights to Gene Therapy OCU400 - marketscreener.com
Ocugen inks $11 million gene therapy deal for Korean market By Investing.com - Investing.com Canada
Ocugen announcing signing of term sheet, enter licensing agreement for OCU400 - TipRanks
오큐젠 (OCGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.69%
2.49%
자본화:
|
볼륨(24시간):